Amphastar Pharmaceuticals, Inc.: Form 10-Q for the period ended Jun 30, 2014
Filed with the SEC on Aug 13, 2014 and accepted by EDGAR at Aug 13, 2014, 16:17 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2014-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2014-04-01 to 2014-06-30 | $49.0m | us-gaap:SalesRevenueNet |
| Revenue | 6 months2014-01-01 to 2014-06-30 | $94.9m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months2014-04-01 to 2014-06-30 | $34.0m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2014-01-01 to 2014-06-30 | $67.4m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2014-04-01 to 2014-06-30 | $15.0m | us-gaap:GrossProfit |
| Gross profit | 6 months2014-01-01 to 2014-06-30 | $27.5m | us-gaap:GrossProfit |
| Research and development | 3 months2014-04-01 to 2014-06-30 | $6.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2014-01-01 to 2014-06-30 | $12.2m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2014-04-01 to 2014-06-30 | −$1.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2014-01-01 to 2014-06-30 | −$3.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2014-04-01 to 2014-06-30 | $476.0k | us-gaap:InterestExpense |
| Interest expense | 6 months2014-01-01 to 2014-06-30 | $655.0k | us-gaap:InterestExpense |
| Income tax | 3 months2014-04-01 to 2014-06-30 | −$696.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2014-01-01 to 2014-06-30 | −$1.5m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2014-04-01 to 2014-06-30 | −$1.2m | us-gaap:NetIncomeLoss |
| Net income | 6 months2014-01-01 to 2014-06-30 | −$2.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2014-04-01 to 2014-06-30 | −$0.03 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2014-01-01 to 2014-06-30 | −$0.07 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2014-04-01 to 2014-06-30 | −$0.03 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2014-01-01 to 2014-06-30 | −$0.07 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2014-04-01 to 2014-06-30 | 39,767,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2014-01-01 to 2014-06-30 | 39,268,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2014-01-01 to 2014-06-30 | −$4.9m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 6 months2014-01-01 to 2014-06-30 | $7.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2014-06-30 | $64.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2014-06-30 | $214.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2014-06-30 | $397.3m | us-gaap:Assets |
| Current liabilities | At period end2014-06-30 | $56.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2014-06-30 | $109.5m | us-gaap:Liabilities |
| Shareholders' equity | At period end2014-06-30 | $287.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001171843-14-003951. Last ingested by Listed: Nov 6, 2026, 17:01 ET. Listed shows no prices and gives no investment advice.